Dravet Syndrome Treatment News and Information

What is Dravet Syndrome? (Definition)

According to the Epilepsy Foundation, Dravet syndrome is a rare genetic epileptic encephalopathy (dysfunction of the brain). It begins in the first year of life in an otherwise healthy infant. Prior to 1989, this syndrome was known as epilepsy with polymorphic seizures, polymorphic epilepsy in infancy (PMEI) or severe myoclonic epilepsy in infancy (SMEI). The disease begins in infancy but is lifelong.

See below for updated news and information regarding Dravet Syndrome including new medical research, treatment options and advancements. 

Latest Dravet Syndrome News

Epilepsy News: Scientists Find Compound Shows Potential to Protect Against Febrile Seizures

(EMORY HEALTH SCIENCES) According to a recent press release, the compound huperzine A can increase resistance to induced seizures in mouse models of genetic epilepsy, scientists at Emory University School of Medicine have found. In particular, huperzine A shows potential for protecting against febrile seizures, which are a feature of both Dravet syndrome, a severe form of childhood epilepsy, and ...
Read More

Lead Compound BIS-001 Eliminates Seizures in Majority of Animals in Models of Dravet Syndrome

(PRNewswire) Biscayne Pharmaceuticals, Inc., today reported that a new scientific publication shows that lead compound BIS-001 can eliminate all seizures in the majority of animals in models of the catastrophic type of epilepsy known as Dravet syndrome. BIS-001 is a clinical-stage, highly potent agent with a novel mechanism of action that is a synthetic form of huperzine A, an extract of ...
Read More